What Quest Diagnostics’ recent performance tells you Quest Diagnostics (DGX) has attracted fresh attention after recent share gains, with the stock up about 16% over the past month and roughly 12% ...

Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that Benjamin Beauvalot ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Quest Diagnostics Incorporated stock has reached an all-time high, hitting a price of $213.35. This milestone reflects a significant upward trend for the company over the past year. The stock has ...

Analysts estimate that Quest Diagnostics will report an earnings per share (EPS) of $2.35. Anticipation surrounds Quest Diagnostics's announcement, with investors hoping to hear about both surpassing ...

Quest Diagnostics named Dr. Yuri Fesko, a seasoned health care executive and oncologist, its new senior vice president and chief medical officer. In a Dec. 20 press release announcing the appointment, ...

Quest Diagnostics may be the preferred lab your health insurance, doctors, or specialists use for blood work or other samples. We’re reviewing its sub-brand Quest Health, from which you can order your ...

In the last three months, 7 analysts have published ratings on Quest Diagnostics (NYSE:DGX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...

Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging ...

Quest Diagnostics Incorporated (NYSE:DGX) Q4 2025 Earnings Call Transcript February 10, 2026 Quest Diagnostics Incorporated misses on earnings expectations. Reported EPS is $2.19 EPS, expectations ...

One of the top diagnostics specialists on the market published quarterly and full-year results. It not only scored a double beat on analyst projections, but its revenue guidance came out ahead as well ...

Quest Diagnostics (NASDAQ:DGX) posted better-than-expected earnings for the third quarter on Tuesday. While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the ...